1
|
Gierski F, Benzerouk F, Jeanblanc J, Angerville B, Dervaux A, Kaladjian A, Naassila M. Validity and usefulness of the short form of the Drinking Motives Questionnaire Revised (DMQ-R SF) among patients with schizophrenia. Addict Behav 2022; 129:107251. [PMID: 35093808 DOI: 10.1016/j.addbeh.2022.107251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 12/21/2021] [Accepted: 01/14/2022] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Drinking motives are considered to be major predictors of alcohol consumption and alcohol-related problems. However, these motives have been poorly investigated in patients with schizophrenia. The aim of the present study among patients with schizophrenia was twofold: 1) assess the validity of the short form of the Drinking Motives Questionnaire-Revised (DMQ-R SF); and 2) investigate the relationship between drinking motives and comorbid alcohol use disorder (AUD). METHOD A total of 179 patients with schizophrenia were approached to participate in the study. DSM-5 criteria were used to identify patients with comorbid AUD (AUD+; n = 42) and non-abstainers patients without comorbid AUD (AUD-; n = 71). RESULTS A confirmatory factor analysis conducted on items of the DMQ-R SF for the whole sample revealed adequate goodness-of-fit values, while internal consistency indices were globally satisfactory. Group comparisons revealed higher use of alcohol and other substances, as well as stronger drinking motives among AUD + patients, while groups were comparable concerning clinical features of schizophrenia, including psychotic symptom dimensions and severity. Regression analysis showed that the Alcohol Use Disorder Identification Test score was significantly associated with two internal drinking motives: enhancement and coping. CONCLUSIONS Findings suggest that the DMQ-R SF is a reliable tool for assessing drinking motives among patients with schizophrenia. Enhancement and coping motives seem to play a major role in comorbid AUD among these patients. Community-based and clinical treatment programs should take the drinking motives of dual-diagnosis patients into consideration, in order to improve their outcomes.
Collapse
Affiliation(s)
- Fabien Gierski
- Cognition Health Society Laboratory (C2S - EA 6291), University of Reims Champagne Ardenne, Reims, France; Department of Psychiatry, Marne Public Mental Health Institution & Reims University Hospital, Reims, France; Research Group on Alcohol and Dependences, INSERM & University of Picardy Jules Verne, Amiens, France; Department of Psychiatry and Addiction, Amiens University Hospital, Amiens, France; Institute of Psychiatry and Addictions, Paris, France.
| | - Farid Benzerouk
- Cognition Health Society Laboratory (C2S - EA 6291), University of Reims Champagne Ardenne, Reims, France; Department of Psychiatry, Marne Public Mental Health Institution & Reims University Hospital, Reims, France; Institute of Psychiatry and Addictions, Paris, France
| | - Jérôme Jeanblanc
- Research Group on Alcohol and Dependences, INSERM & University of Picardy Jules Verne, Amiens, France; Institute of Psychiatry and Addictions, Paris, France
| | - Bernard Angerville
- Research Group on Alcohol and Dependences, INSERM & University of Picardy Jules Verne, Amiens, France; Department of Psychiatry and Addiction, Amiens University Hospital, Amiens, France; Institute of Psychiatry and Addictions, Paris, France
| | - Alain Dervaux
- Research Group on Alcohol and Dependences, INSERM & University of Picardy Jules Verne, Amiens, France; Department of Psychiatry and Addiction, Amiens University Hospital, Amiens, France; Institute of Psychiatry and Addictions, Paris, France
| | - Arthur Kaladjian
- Cognition Health Society Laboratory (C2S - EA 6291), University of Reims Champagne Ardenne, Reims, France; Department of Psychiatry, Marne Public Mental Health Institution & Reims University Hospital, Reims, France; Institute of Psychiatry and Addictions, Paris, France
| | - Mickaël Naassila
- Research Group on Alcohol and Dependences, INSERM & University of Picardy Jules Verne, Amiens, France; Institute of Psychiatry and Addictions, Paris, France
| |
Collapse
|
2
|
Carrà G, Johnson S, Crocamo C, Angermeyer MC, Brugha T, Azorin JM, Toumi M, Bebbington PE. Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. Psychiatry Res 2016; 239:301-7. [PMID: 27046394 DOI: 10.1016/j.psychres.2016.03.038] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 01/27/2016] [Accepted: 03/23/2016] [Indexed: 10/22/2022]
Abstract
Little is known about the correlates of comorbid drug and alcohol dependence in people with schizophrenia outside the USA. We tested hypotheses that dependence on alcohol/drugs would be associated with more severe symptoms, and poorer psychosocial functioning and quality of life. The EuroSC Cohort study (N=1204), based in France, Germany and the UK, used semi-structured clinical interviews for diagnoses, and standardized tools to assess correlates. We used mixed models to compare outcomes between past-year comorbid dependence on alcohol/drugs, controlling for covariates and modelling both subject and country-level effects. Participants dependent on alcohol or drugs had fewer negative symptoms on PANSS than their non-dependent counterparts. However, those dependent on alcohol scored higher on PANSS general psychopathology than those who were not, or dependent only on drugs. People with schizophrenia dependent on drugs had poorer quality of life, more extrapyramidal side effects, and scored worse on Global Assessment of Functioning (GAF) than those without dependence. People with alcohol dependence reported more reasons for non-compliance with medication, and poorer functioning on GAF, though not on Global Assessment of Relational Functioning. In people with schizophrenia, comorbid dependence on alcohol or drugs is associated with impaired clinical and psychosocial adjustment, and poorer quality of life.
Collapse
Affiliation(s)
- Giuseppe Carrà
- Division of Psychiatry (Formerly Mental Health Sciences), University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK.
| | - Sonia Johnson
- Division of Psychiatry (Formerly Mental Health Sciences), University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK.
| | - Cristina Crocamo
- Department of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Via Forlanini 2, 27100 Pavia, Italy.
| | - Matthias C Angermeyer
- Department of Psychiatry, University of Leipzig, Johannisallee 20, 04137 Leipzig, Germany.
| | - Traolach Brugha
- Department of Health Sciences, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, UK.
| | - Jean-Michel Azorin
- SHU Psychiatrie Adultes, Hôpital Sainte Marguerite, 13274 Marseille Cedex 9, France.
| | - Mondher Toumi
- Chair of Market Access, University Claude Bernard Lyon I, UFR d'Odontologie 11, Rue Guillaume Paradin, 69008 Lyon, France.
| | - Paul E Bebbington
- Division of Psychiatry (Formerly Mental Health Sciences), University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T 7NF, UK.
| |
Collapse
|
3
|
Jeanblanc J, Balguerie K, Coune F, Legastelois R, Jeanblanc V, Naassila M. Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia. Addict Biol 2015; 20:490-9. [PMID: 24725220 DOI: 10.1111/adb.12146] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Schizophrenia is a mental disorder characterized by a series of positive, negative or cognitive symptoms but with also the particularity of exhibiting a high rate of co-morbid use of drugs of abuse. While more than 80% of schizophrenics are smokers, the second most consumed drug is alcohol, with dramatic consequences on frequency and intensity of psychotic episodes and on life expectancy. Here we investigated the impact of light alcohol intake during adolescence on the subsequent occurrence of alcohol addiction-like behavior in neonatal ventral hippocampal lesion (NVHL) rats, a neurodevelopmental model of schizophrenia. Our findings demonstrated an increased liability to addictive behaviors in adult NVHL rats after voluntary alcohol intake during adolescence. NVHL rats displayed several signs of alcohol use disorder such as a loss of control over alcohol intake and high motivation to consume alcohol, associated with a higher resistance to extinction. In addition, once NVHL rats relapsed, they maintained higher drinking levels than controls. We finally showed that the anti-addictive drug naltrexone is efficient in reducing excessive alcohol intake in NVHL rats. Our results are in accordance with epidemiological studies underlying the particular vulnerability to alcohol addiction after adolescent exposure to alcohol and highlight the fact that schizophrenic subjects may be particularly at risk even after light alcohol consumption. Based on these results, it seems particularly relevant to prevent early onset of alcohol use in at-risk subjects and thus to reduce the incidence of co-morbid alcohol abuse in psychotic patients.
Collapse
Affiliation(s)
- Jérôme Jeanblanc
- Groupe de Recherche sur l'Alcool et les Pharmacodépendances-INSERM ERI 24; UFR de Pharmacie; SFR CAP Santé; Université de Picardie Jules Verne; France
| | - Kevin Balguerie
- Groupe de Recherche sur l'Alcool et les Pharmacodépendances-INSERM ERI 24; UFR de Pharmacie; SFR CAP Santé; Université de Picardie Jules Verne; France
| | - Fabien Coune
- Groupe de Recherche sur l'Alcool et les Pharmacodépendances-INSERM ERI 24; UFR de Pharmacie; SFR CAP Santé; Université de Picardie Jules Verne; France
| | | | - Virginie Jeanblanc
- Plateforme Animalerie du Pôle Santé; Université de Picardie Jules Verne; France
| | - Mickaël Naassila
- Groupe de Recherche sur l'Alcool et les Pharmacodépendances-INSERM ERI 24; UFR de Pharmacie; SFR CAP Santé; Université de Picardie Jules Verne; France
| |
Collapse
|
4
|
Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009; 23:193-212. [PMID: 19320529 DOI: 10.2165/00023210-200923030-00002] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.
Collapse
Affiliation(s)
- Pierre Thomas
- Department of Psychiatry, University of Lille Medical School, Lille, France.
| | | | | | | | | | | |
Collapse
|
5
|
Abstract
UNLABELLED Whereas observations of psychotic disorders induced by amphetamines are common, few observations described the impact of chronic amphetamine abuse on schizophrenic patients. We report the case of a schizophrenic patient who presented with amphetamine dependence for several years, without other accompanying addiction. CASE REPORT During his adolescence, Mr. X. gradually developed delusional beliefs of persecution and telepathy. He believed that the other pupils and teachers spoke about him in malicious terms. At the age of 23, Mr. X began to consume 60-100 mg/week of amphetamines orally. He consumed amphetamines during 7 years. The delusions, in particular the auditory hallucinations worsened after the use of amphetamines. Subsequently, he married and was declared unfit for national service due to the psychotic disorders. Mr. X received neuroleptic treatment with moderate effects on the psychotic symptoms. Between the age of 24 and 30, the patient presented persecutory, megalomanic and physical transformation beliefs, delusions of being controlled as well as auditory, somatic-tactile and visual hallucinations. At the age of 30, while he had stopped his consumption of amphetamines for 9 months, the patient, overwhelmed with the delusions, murdered his wife. He was sent in jail for 13 months, and subsequently hospitalized for one year in a high security psychiatric department and 7 years in our psychiatric department. The neuroleptic treatment was effective, particularly against the hallucinations. Following stabilisation, the symptomatology of the patient was marked by a disorganization syndrome, including prominent thought disorder, disorganized speech, associative loosening, frequent derailments and negative signs of schizophrenia, in particular affective flattening and blunting of emotional expression. When the patient was 43, a trial discharge was authorized owing to improvement of his condition. The neuroleptic treatment was switched with single-drug olanzapine therapy, 10 mg/day which improved the negative symptoms. Mr. X. resumed part-time professional activities and remarried. DISCUSSION The patient fulfilled the DSM IV criteria for schizophrenia and for amphetamine dependence assessed using the Composite International Diagnostic Interview (CIDI). He presented, in particular, withdrawal syndrome when amphetamines were discontinued. The amphetamine consumption was followed by a marked deterioration in the delusions, particularly the hallucinations. Worsening of the positive symptoms in schizophrenic patients by amphetamines has been established in single dose studies, in particular characterized by persecutory delusions and hallucinations. On the other hand, amphetamines tend to transiently and moderately reduce the negative symptoms. Some stu-dies have shown that amphetamine consumption promoted violent acting out in non-schizophrenic subjects. In our observation, the acting out may be not related to the acute effects of these substances, since it occurred 9 months after stated discontinuation of amphetamine consumption. However, the cerebral toxicity and psycho-behavioural disturbances related to amphetamines might be prolonged after withdrawal. In non-schizophrenic patients, the existence of prolonged neurotoxicity of amphetamines and related psycho-behavioral disturbances has been suggested. The prolonged administration of amphetamines to animals produces neuro-axonal degeneration in the striatum, the frontal cortex, the nucleus accumbens and the amygdala. In human, there are some evidence of persistant deteriorations of the serotoninergic and dopaminergic systems in the caudate nucleus, the putamen and the nucleus accumbens following amphetamine consumption. CONCLUSION The neurobiological and psycho-behavioural effects of amphetamines may be prolonged following withdrawal in both schizophrenic and non-schizophrenic patients.
Collapse
Affiliation(s)
- A Dervaux
- Service de Psychiatrie, BP 27, Centre Hospitalier Général, F-91401 Orsay
| | | | | |
Collapse
|
6
|
Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE 2003; 48:14-21. [PMID: 12635559 DOI: 10.1177/070674370304800104] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To review the current knowledge on the problem of psychoactive substance abuse by persons with schizophrenia, with particular attention to issues of direct relevance to clinical practice. METHOD The author examined the literature from the last 2 decades and data from studies in which he was involved. RESULTS Schizophrenia sufferers show an elevated liability for substance abuse. Such comorbidity may derive from self-medication attempts, a common neuropathology for addiction and schizophrenia, the psychotogenic properties of certain drugs, or the influence of environmental factors. Among schizophrenia patients receiving treatment, substance misuse is associated with more severe symptoms and poorer therapeutic response. The presence of a chronic psychosis impedes treatment of the substance problem in traditional, nonpsychiatric addiction programs. Better outcomes are observed in integrated therapy services, where patients receive appropriate care for both conditions. CONCLUSION Dual-pathology patients need comprehensive care with appropriate pharmacotherapy and psychosocial interventions. This treatment can be best provided within the context of a continuing care psychiatric service.
Collapse
Affiliation(s)
- Juan C Negrete
- Montreal General Hospital, 1650 Cedar Avenue, Montreal, QC H3G 1A4.
| |
Collapse
|
7
|
Daban C, Amado I, Baylé F, Gut A, Willard D, Bourdel MC, Loo H, Olié JP, Millet B, Krebs MO, Poirier MF. Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Res 2002; 113:83-92. [PMID: 12467948 DOI: 10.1016/s0165-1781(02)00228-7] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The aim of this study is to circumscribe the cognitive deficits according to schizophrenic syndromes in a population of sub-acute untreated patients. We have studied the cross-sectional correlation between cognitive deficits and schizophrenic symptoms, in a group of 24 untreated patients (including 17 neuroleptic-naive patients) with recent onset of the disease. A task of alertness, a working memory (WM) test (including two levels of difficulty) and an abbreviated version of the Wisconsin Card Sorting Test (WCST) were selected. WM deficits and poor performance on the WCST were highly correlated with disorganized symptoms, modestly with the positive syndrome and not with the negative syndrome. Thus, disorganized symptoms, more than any other, appear to be related to the impairment of executive function and WM in recent onset unmedicated patients with schizophrenia.
Collapse
Affiliation(s)
- Claire Daban
- E0117 INSERM Paris V, Service Hospitalo-Universitaire, Hôpital Sainte-Anne, 7 rue Cabanis, 75014, Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|